|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Di Leo A et al. Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients. Proc ASCO 2007;Abstract 1011.Geyer CE et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43. Abstract
Joensuu H et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract
O’Shaughnessy J et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Proc ASCO 2008;Abstract 1015.
Paik S et al. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008;358(13):1409-11. No abstract available
Paik S et al. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31. Proc ASCO 2007;Abstract 511.
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
Seidman A et al. Randomized Phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B Protocol 9840. J Clin Oncol 2008;26(10):1642-9. Abstract
Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006;Abstract 52.
Smith I et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369(9555):29-36. Abstract
 |
 |
EDITOR
Neil Love, MD
INTERVIEWS
Nancy E Davidson, MD
- Select publications
Professor John Crown, MD
- Select publications
Kathy D Miller, MD
- Select publications
Peter M Ravdin, MD, PhD
- Select publications
THREE PERSPECTIVES ON US COOPERATIVE GROUP RESEARCH
Norman Wolmark, MD
- Select publications
Joyce O’Shaughnessy, MD
- Select publications
Eric P Winer, MD
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
